// App-Quantinova.ai

2137 : Impact of Patient Characteristics, Including Sex, on the Efficacy of Upadacitinib Compared with Adalimumab in Patients with Psoriatic Arthritis

Researchers

Presenter

  • Lihi Eder

Principal Investigators

  • Laura Coates

  • Peter Nash

  • Uta Kiltz

  • Ennio Lubrano

  • Erin McDearmon-Blondell

  • Tianming Gao

  • Alexis Ogdie

Medical Centers

  • Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada

  • Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences,, Oxford University Hospitals NHS Trust, Oxford, UK, Oxford, United Kingdom

  • School of Medicine, Griffith University, QLD, Australia, Brisbane, Australia

  • 15. Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ’Vincenzo Tiberio’, University of Molise, Campobasso, Italy

  • Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

  • Rheumazentrum Ruhrgebiet, Herne, Germany

Locations

  • Canada

  • United Kingdom

  • Australia

  • Germany

  • Italy

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

Biomarkers

  • C reactive protein

  • Plasminogen Activator, Urokinase

  • High sensitivity C-reactive protein

  • Body mass index

  • Albumin/creatinine

Drug/Treatment

  • ABT-494

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT03104400

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved